B
Bella Ungar
Researcher at Sheba Medical Center
Publications - 102
Citations - 2485
Bella Ungar is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Ulcerative colitis & Infliximab. The author has an hindex of 20, co-authored 72 publications receiving 1960 citations. Previous affiliations of Bella Ungar include Tel Aviv University.
Papers
More filters
Journal ArticleDOI
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar,Idan Levy,Yarden Yavne,Miri Yavzori,Orit Picard,Ella Fudim,Ronen Loebstein,Yehuda Chowers,Rami Eliakim,Uri Kopylov,Shomron Ben-Horin +10 more
TL;DR: It is proposed that serum levels of 6-10 μg/mL for infliximab and 8-12 μg/ mL for adalimumab are required to achieve mucosal healing in 80%-90% of patients with IBD, and that this could be considered as a "therapeutic window."
Journal ArticleDOI
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar,Yehuda Chowers,Miri Yavzori,Orit Picard,Ella Fudim,Ofir Har-Noy,Uri Kopylov,Rami Eliakim,Shomron Ben-Horin +8 more
TL;DR: Serial measurements showed that ATI development often preceded the onset of clinical flare, and survival free of clinical loss of response was enjoyed by 51% of patients, and serial measurements showed this incidence is reduced by concomitant immunomodulator even in scheduled-therapy patients.
Journal ArticleDOI
Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
Henit Yanai,Henit Yanai,Lev Lichtenstein,Lev Lichtenstein,Amit Assa,Yoav Mazor,Batia Weiss,Batia Weiss,Arie Levine,Arie Levine,Yulia Ron,Yulia Ron,Uri Kopylov,Uri Kopylov,Yoram Bujanover,Yoram Bujanover,Yoram Rosenbach,Bella Ungar,Bella Ungar,Rami Eliakim,Rami Eliakim,Yehuda Chowers,Raanan Shamir,Gerald Fraser,Gerald Fraser,Iris Dotan,Iris Dotan,Shomron Ben-Horin,Shomron Ben-Horin +28 more
TL;DR: The results of this retrospective analysis suggest that trough levels of drug or ADAs may guide therapeutic decisions for more than two-thirds of inflammatory bowel disease patients with either clinically suspected or definite inflammatory loss of response to therapy.
Journal ArticleDOI
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
Shomron Ben-Horin,Miri Yavzori,Itai Benhar,Ella Fudim,Orit Picard,Bella Ungar,Soo Young Lee,Sung Hwan Kim,Rami Eliakim,Yehuda Chowers +9 more
TL;DR: Anti-Remicade antibodies in patients with IBD recognise and functionally inhibit Remsima to a similar degree, suggesting similar immunogenicity and shared immunodominant epitopes on these two infliximab agents.
Journal ArticleDOI
Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
TL;DR: VDZ is efficacious in CD and UC and has a favourable safety profile in RWE studies, which is summarized in this systematic review.